---
document_datetime: 2025-12-29 10:08:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/refixia.html
document_name: refixia.html
version: success
processing_time: 0.1162048
conversion_datetime: 2025-12-30 10:06:02.682029
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Refixia

[RSS](/en/individual-human-medicine.xml/66297)

##### Authorised

This medicine is authorised for use in the European Union

nonacog beta pegol Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Refixia](#news-on)
- [More information on Refixia](#more-information-on-refixia-657)
- [More information on Refixia](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Refixia. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Refixia.

For practical information about using Refixia, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Refixia and what is it used for?

Refixia is a medicine used to treat and prevent bleeding in patients with haemophilia B, an inherited bleeding disorder caused by lack of a clotting protein called factor IX. It can be used in adults and children from 12 years of age.

Refixia contains the active substance nonacog beta pegol.

## How is Refixia used?

Refixia can only be obtained with a prescription and treatment should be under the supervision of a doctor who has experience in the treatment of haemophilia.

Refixia is available as a powder and a liquid that are mixed together to make a solution for injection into a vein. The dose and frequency of treatment depend on whether Refixia is used to treat or prevent bleeding, or to reduce bleeding during surgery, the extent and location of the bleeding, and the patient's bodyweight. For further information on how to use this medicine, see the summary of product characteristics (also part of the EPAR).

Patients or their carers may be able to inject Refixia themselves at home once they have been trained appropriately. For full details, see the package leaflet.

## How does Refixia work?

Patients with haemophilia B lack factor IX, a protein needed for normal clotting of the blood, and as a result, they bleed readily. The active substance in Refixia, nonacog beta pegol, works in the body in the same way as human factor IX. It replaces the missing factor IX, thereby helping the blood to clot and giving temporary control of bleeding.

## What benefits of Refixia have been shown in studies?

Refixia has been shown to be effective at both treating bleeding episodes and keeping the number of episodes low.

In a study involving 74 adults and adolescents aged 13 or above, 29 patients given Refixia as a weekly preventive treatment had around 1 bleeding episode a year, and 15 patients given Refixia for treating bleedings 'on demand' had around 16 bleeding episodes a year. In addition, when bleeding did occur, Refixia was rated excellent or good at treating around 92% of bleeding episodes. 87% of bleeding episodes resolved with one injection of Refixia.

In the second study in 25 children aged below 13 years, all patients were given Refixia as a weekly preventive treatment. Patients had around 1 bleeding episode per year and Refixia was rated excellent or good at treating around 93% of bleeding episodes. Around 86% of bleeding episodes resolved with one injection.

## What are the risks associated with Refixia?

Hypersensitivity (allergic) reactions are uncommon with Refixia (may affect up to 1 in 100 patients) and may include: swelling, burning and stinging at the injection site, chills, flushing, itchy rash, headache, hives, low blood pressure, lethargy, nausea and vomiting, restlessness, a fast heartbeat, tightness of the chest and wheezing. In some cases these reactions can become severe.

Some patients taking factor IX medicines may develop inhibitors (antibodies) against factor IX, causing the medicine to stop working and resulting in a loss of bleeding control. Factor IX medicines can also potentially cause problems due to the formation of blood clots in the blood vessels.

Refixia must not be used in patients allergic to hamster proteins. For the full list of side effects and restrictions, see the package leaflet.

## Why is Refixia approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Refixia's benefits are greater than its risks and recommended that it be approved for use in the EU.

Studies show that Refixia is effective at preventing and treating bleeding episodes in patients with haemophilia B and its safety is comparable to that of other factor IX products. However, part of the active substance in Refixia (called PEG) may accumulate in the body, including in a structure in the brain called choroid plexus, following long-term treatment. Since this could potentially cause problems especially in children below 12 years of age, Refixia is only approved for use in in adults and children from 12 years of age.

## What measures are being taken to ensure the safe and effective use of Refixia?

The company that markets Refixia will conduct a study to investigate the potential effects of PEG accumulation in the choroid plexus of the brain and other organs.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Refixia have been included in the summary of product characteristics and the package leaflet.

## Other information about Refixia

The European Commission granted a marketing authorisation valid throughout the European Union for Refixia on 02 June 2017.

For more information about treatment with Refixia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Refixia : EPAR - Summary for the public

Reference Number: EMEA/H/C/004178

English (EN) (116.92 KB - PDF)

**First published:** 02/08/2017

**Last updated:** 06/11/2023

[View](/en/documents/overview/refixia-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-590)

български (BG) (135.06 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/bg/documents/overview/refixia-epar-summary-public_bg.pdf)

español (ES) (108.02 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/es/documents/overview/refixia-epar-summary-public_es.pdf)

čeština (CS) (132.03 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/cs/documents/overview/refixia-epar-summary-public_cs.pdf)

dansk (DA) (108.59 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/da/documents/overview/refixia-epar-summary-public_da.pdf)

Deutsch (DE) (112.31 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/de/documents/overview/refixia-epar-summary-public_de.pdf)

eesti keel (ET) (106.35 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/et/documents/overview/refixia-epar-summary-public_et.pdf)

ελληνικά (EL) (136.7 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/el/documents/overview/refixia-epar-summary-public_el.pdf)

français (FR) (110.31 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/fr/documents/overview/refixia-epar-summary-public_fr.pdf)

hrvatski (HR) (132.69 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/hr/documents/overview/refixia-epar-summary-public_hr.pdf)

italiano (IT) (107.17 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/it/documents/overview/refixia-epar-summary-public_it.pdf)

latviešu valoda (LV) (139.29 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/lv/documents/overview/refixia-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (131.53 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/lt/documents/overview/refixia-epar-summary-public_lt.pdf)

magyar (HU) (131.13 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/hu/documents/overview/refixia-epar-summary-public_hu.pdf)

Malti (MT) (132.64 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/mt/documents/overview/refixia-epar-summary-public_mt.pdf)

Nederlands (NL) (109.76 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/nl/documents/overview/refixia-epar-summary-public_nl.pdf)

polski (PL) (134.51 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/pl/documents/overview/refixia-epar-summary-public_pl.pdf)

português (PT) (108.89 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/pt/documents/overview/refixia-epar-summary-public_pt.pdf)

română (RO) (128.74 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/ro/documents/overview/refixia-epar-summary-public_ro.pdf)

slovenčina (SK) (133.77 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/sk/documents/overview/refixia-epar-summary-public_sk.pdf)

slovenščina (SL) (130.77 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/sl/documents/overview/refixia-epar-summary-public_sl.pdf)

Suomi (FI) (105.73 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/fi/documents/overview/refixia-epar-summary-public_fi.pdf)

svenska (SV) (107.23 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

06/11/2023

[View](/sv/documents/overview/refixia-epar-summary-public_sv.pdf)

Refixia : EPAR - Risk management plan

English (EN) (2.84 MB - PDF)

**First published:** 17/06/2020

**Last updated:** 25/11/2025

[View](/en/documents/rmp/refixia-epar-risk-management-plan_en.pdf)

## Product information

Refixia : EPAR - Product Information

English (EN) (354.52 KB - PDF)

**First published:** 02/08/2017

**Last updated:** 25/11/2025

[View](/en/documents/product-information/refixia-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-951)

български (BG) (466.02 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/bg/documents/product-information/refixia-epar-product-information_bg.pdf)

español (ES) (360.89 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/es/documents/product-information/refixia-epar-product-information_es.pdf)

čeština (CS) (441.19 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/cs/documents/product-information/refixia-epar-product-information_cs.pdf)

dansk (DA) (349.52 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/da/documents/product-information/refixia-epar-product-information_da.pdf)

Deutsch (DE) (367.5 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/de/documents/product-information/refixia-epar-product-information_de.pdf)

eesti keel (ET) (360.83 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/et/documents/product-information/refixia-epar-product-information_et.pdf)

ελληνικά (EL) (497.22 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/el/documents/product-information/refixia-epar-product-information_el.pdf)

français (FR) (375.83 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/fr/documents/product-information/refixia-epar-product-information_fr.pdf)

hrvatski (HR) (419.36 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/hr/documents/product-information/refixia-epar-product-information_hr.pdf)

íslenska (IS) (355.83 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/is/documents/product-information/refixia-epar-product-information_is.pdf)

italiano (IT) (364.21 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/it/documents/product-information/refixia-epar-product-information_it.pdf)

latviešu valoda (LV) (435.22 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/lv/documents/product-information/refixia-epar-product-information_lv.pdf)

lietuvių kalba (LT) (461.27 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/lt/documents/product-information/refixia-epar-product-information_lt.pdf)

magyar (HU) (457.07 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/hu/documents/product-information/refixia-epar-product-information_hu.pdf)

Malti (MT) (555.66 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/mt/documents/product-information/refixia-epar-product-information_mt.pdf)

Nederlands (NL) (388.05 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/nl/documents/product-information/refixia-epar-product-information_nl.pdf)

norsk (NO) (347.9 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/no/documents/product-information/refixia-epar-product-information_no.pdf)

polski (PL) (504.71 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/pl/documents/product-information/refixia-epar-product-information_pl.pdf)

português (PT) (353.31 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/pt/documents/product-information/refixia-epar-product-information_pt.pdf)

română (RO) (450.66 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/ro/documents/product-information/refixia-epar-product-information_ro.pdf)

slovenčina (SK) (440.9 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/sk/documents/product-information/refixia-epar-product-information_sk.pdf)

slovenščina (SL) (454.39 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/sl/documents/product-information/refixia-epar-product-information_sl.pdf)

Suomi (FI) (346.08 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/fi/documents/product-information/refixia-epar-product-information_fi.pdf)

svenska (SV) (350.89 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

25/11/2025

[View](/sv/documents/product-information/refixia-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000249232 04/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Refixia : EPAR - All Authorised presentations

English (EN) (28.23 KB - PDF)

**First published:** 02/08/2017

**Last updated:** 16/12/2022

[View](/en/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-565)

български (BG) (57.92 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/bg/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_bg.pdf)

español (ES) (25.22 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/es/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_es.pdf)

čeština (CS) (54.97 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/cs/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (30.35 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/da/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (29.98 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/de/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (28.22 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/et/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (53.97 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/el/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_el.pdf)

français (FR) (30.71 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/fr/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (56.51 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/hr/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (28.15 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/is/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_is.pdf)

italiano (IT) (28.24 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/it/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (55.25 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/lv/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (51.54 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/lt/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.02 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/hu/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (53.15 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/mt/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (28.88 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/nl/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (30.16 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/no/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_no.pdf)

polski (PL) (53.66 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/pl/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_pl.pdf)

português (PT) (29.21 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/pt/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.97 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/ro/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.96 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/sk/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (37.49 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/sl/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (29.56 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/fi/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (25.98 KB - PDF)

**First published:**

02/08/2017

**Last updated:**

16/12/2022

[View](/sv/documents/all-authorised-presentations/refixia-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Refixia Active substance nonacog beta pegol International non-proprietary name (INN) or common name nonacog beta pegol Therapeutic area (MeSH) Hemophilia B Anatomical therapeutic chemical (ATC) code B02BD04

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

## Authorisation details

EMA product number EMEA/H/C/004178

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Novo Nordisk A/S

Novo Alle 2880 Bagsvaerd Denmark

Opinion adopted 23/03/2017 Marketing authorisation issued 02/06/2017 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Refixia : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.04 KB - PDF)

**First published:** 25/11/2025

[View](/en/documents/procedural-steps-after/refixia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Refixia : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (137.47 KB - PDF)

**First published:** 17/06/2020

**Last updated:** 25/11/2025

[View](/en/documents/procedural-steps-after/refixia-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Refixia-H-C-004178-P46-008 : EPAR - Assessment report

Adopted

Reference Number: EMA/511432/2024

English (EN) (2.3 MB - PDF)

**First published:** 08/11/2024

[View](/en/documents/variation-report/refixia-h-c-004178-p46-008-epar-assessment-report_en.pdf)

Refixia-H-C-4178-II-0032 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/319611/2023

English (EN) (6.47 MB - PDF)

**First published:** 14/12/2023

[View](/en/documents/variation-report/refixia-h-c-4178-ii-0032-epar-assessment-report-variation_en.pdf)

Refixia : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/CHMP/278050/2023

English (EN) (111.04 KB - PDF)

**First published:** 06/11/2023

[View](/en/documents/pip-compliance/refixia-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

CHMP post-authorisation summary of positive opinion for Refixia (II-32)

Adopted

Reference Number: EMA/265277/2023

English (EN) (118.95 KB - PDF)

**First published:** 23/06/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-refixia-ii-32_en.pdf)

## Initial marketing authorisation documents

Refixia : EPAR - Public assessment report

Adopted

Reference Number: EMA/346525/2017

English (EN) (5.53 MB - PDF)

**First published:** 02/08/2017

[View](/en/documents/assessment-report/refixia-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Refixia

Adopted

Reference Number: EMA/CHMP/193129/2017

English (EN) (74.74 KB - PDF)

**First published:** 24/03/2017

**Last updated:** 24/03/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-refixia_en.pdf)

#### News on Refixia

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2023) 23/06/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 March 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-march-2017) 24/03/2017

#### More information on Refixia

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu309640) on 15 May 2009. Refixia was withdrawn from the Community register of orphan medicinal products in May 2017 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Refixia

- [EMEA-000731-PIP01-09-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000731-pip01-09-m03)
- [NN7999-4413: Adverse Event Data Collection from External Registries on Nonacog Beta Pegol - post-authorisation study](https://catalogues.ema.europa.eu/study/27138)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 25/11/2025

## Share this page

[Back to top](#main-content)